PMC:7787218 / 11274-12686 JSONTXT

{"project":"LitCovid-PD-HP","denotations":[{"id":"T45","span":{"begin":1266,"end":1278},"obj":"Phenotype"}],"attributes":[{"id":"A45","pred":"hp_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/HP_0010628"}],"text":"The next few months alone are likely to see at least five new vaccines on the U.S. market, with several more in development (Table 1).13 Maintaining public confidence to minimize vaccine hesitancy will be crucial.14,15 As in any post-EUA program, adverse events that were not identified in clinical trials are to be expected. In addition, populations that have been studied in clinical trials may not reflect a predisposition to adverse events that may exist in other populations.16 Regardless of the speed of development, some adverse events are to be expected with all drugs, vaccines, and medicinal products. Fortunately, immune-mediated adverse events are rare. Because we are now entering a period during which millions if not billions of people globally will be exposed to new vaccines over the next several months, we must be prepared to develop strategies to maximize effectiveness and safety at an individual and a population level. The development of systematic and evidence-based approaches to vaccination safety will also be crucial, and the approaches will intersect with our knowledge of vaccine effectiveness and the need for revaccination. When uncommon side effects that are prevalent in the general population are observed (e.g., the four cases of Bell’s palsy reported in the Pfizer–BioNTech vaccine trial group), the question whether they were truly vaccine-related remains to be determined.1"}

{"project":"LitCovid-PubTator","denotations":[{"id":"186","span":{"begin":744,"end":750},"obj":"Species"},{"id":"187","span":{"begin":1266,"end":1278},"obj":"Disease"}],"attributes":[{"id":"A186","pred":"tao:has_database_id","subj":"186","obj":"Tax:9606"},{"id":"A187","pred":"tao:has_database_id","subj":"187","obj":"MESH:D020330"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The next few months alone are likely to see at least five new vaccines on the U.S. market, with several more in development (Table 1).13 Maintaining public confidence to minimize vaccine hesitancy will be crucial.14,15 As in any post-EUA program, adverse events that were not identified in clinical trials are to be expected. In addition, populations that have been studied in clinical trials may not reflect a predisposition to adverse events that may exist in other populations.16 Regardless of the speed of development, some adverse events are to be expected with all drugs, vaccines, and medicinal products. Fortunately, immune-mediated adverse events are rare. Because we are now entering a period during which millions if not billions of people globally will be exposed to new vaccines over the next several months, we must be prepared to develop strategies to maximize effectiveness and safety at an individual and a population level. The development of systematic and evidence-based approaches to vaccination safety will also be crucial, and the approaches will intersect with our knowledge of vaccine effectiveness and the need for revaccination. When uncommon side effects that are prevalent in the general population are observed (e.g., the four cases of Bell’s palsy reported in the Pfizer–BioNTech vaccine trial group), the question whether they were truly vaccine-related remains to be determined.1"}

{"project":"LitCovid-sentences","denotations":[{"id":"T38","span":{"begin":0,"end":325},"obj":"Sentence"},{"id":"T39","span":{"begin":326,"end":611},"obj":"Sentence"},{"id":"T40","span":{"begin":612,"end":665},"obj":"Sentence"},{"id":"T41","span":{"begin":666,"end":941},"obj":"Sentence"},{"id":"T42","span":{"begin":942,"end":1155},"obj":"Sentence"},{"id":"T43","span":{"begin":1156,"end":1412},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The next few months alone are likely to see at least five new vaccines on the U.S. market, with several more in development (Table 1).13 Maintaining public confidence to minimize vaccine hesitancy will be crucial.14,15 As in any post-EUA program, adverse events that were not identified in clinical trials are to be expected. In addition, populations that have been studied in clinical trials may not reflect a predisposition to adverse events that may exist in other populations.16 Regardless of the speed of development, some adverse events are to be expected with all drugs, vaccines, and medicinal products. Fortunately, immune-mediated adverse events are rare. Because we are now entering a period during which millions if not billions of people globally will be exposed to new vaccines over the next several months, we must be prepared to develop strategies to maximize effectiveness and safety at an individual and a population level. The development of systematic and evidence-based approaches to vaccination safety will also be crucial, and the approaches will intersect with our knowledge of vaccine effectiveness and the need for revaccination. When uncommon side effects that are prevalent in the general population are observed (e.g., the four cases of Bell’s palsy reported in the Pfizer–BioNTech vaccine trial group), the question whether they were truly vaccine-related remains to be determined.1"}